Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation / 医学前沿
Frontiers of Medicine
;
(4): 45-56, 2019.
Article
in English
| WPRIM
| ID: wpr-771319
ABSTRACT
Human leukocyte antigen (HLA)-matched donors for hematopoietic stem cell transplantation (HSCT) have long been scarce in China. Haploidentical (haplo) donors are available for the vast majority of patients, but toxicity has limited this approach. Three new approaches for haplo-HSCT originated from Italy, China, and USA in 1990 and have been developed to world-renowned system up to now. The Chinese approach have been greatly improved by implementing new individualized conditioning regimens, donor selection based on non-HLA systems, risk-directed strategies for graft-versus-host disease and relapse, and infection management. Haplo-HSCT has exhibited similar efficacy to HLA-matched HSCT and has gradually become the predominant donor source and the first alternative donor choice for allo-HSCT in China. Registry-based analyses and multicenter studies adhering to international standards facilitated the transformation of the unique Chinese experience into an inspiration for the refinement of global practice. This review will focus on how the new era in which "everyone has a donor" will become a reality in China.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
General Surgery
/
Histocompatibility Testing
/
Randomized Controlled Trials as Topic
/
China
/
Hematopoietic Stem Cell Transplantation
/
Hematologic Neoplasms
/
Transplantation Conditioning
/
Donor Selection
/
Allergy and Immunology
/
Graft vs Host Disease
Type of study:
Controlled clinical trial
/
Practice guideline
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Frontiers of Medicine
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS